Efficacy and Safety of Apremilast in Psoriasis

Ghurki Trust and Teaching Hospital30 enrolled

Overview

Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Psoriasis

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 59 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed patients of chronic plaque psoriasis * patients applicant for oral or parenteral treatments and for light therapy * patients not responding to topical treatments Exclusion Criteria: * Patients who show hypersensitive reactions to apremilast to any of its inactive component * Pregnancy * Lactating mothers

Outcomes

Primary Outcomes

Psoriasis area and severity index

Time frame: 16 weeks

body surface area